XRTX Stock Analysis: Buy, Sell, or Hold?
XRTX - XORTX Therapeutics Inc. Common Stock
$2.08
0.02 (0.97%)
▲
5d:
-5.02%
30d:
-9.96%
90d:
+413.58%
HOLD
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When XRTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: XRTX trades at premium valuation expecting 4.9% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: XRTX trades at premium valuation expecting 4.9% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.47
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$1.53
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 1.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: XRTX is currently trading at $2.08, which is considered oversold relative to its 30-day fair value range of $2.13 to $2.39. From a valuation perspective, the stock is trading at a premium (Forward PE: 1.9) compared to its historical average (1.6). At these levels, the market is pricing in 4.9% annual earnings growth.
Technical Outlook: Technically, XRTX is in a strong uptrend. The price is currently testing key support at $2.08. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: XRTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $14.04 (+574.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, XRTX is in a strong uptrend. The price is currently testing key support at $2.08. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: XRTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $14.04 (+574.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.13 -
$2.39
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 574.8% below Wall St target ($14.04)
- BULLISH: Expecting earnings turnaround to 4.9% growth with None% revenue growth
- CAUTION: Recommendation downgraded due to -5.0% 5-day decline
Trading Range Analysis
30-Day Trading Range
$2.13 -
$2.39
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.09
Resistance Level
$2.60
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.89
Wall Street Target
$14.04
(+574.8%)
Earnings Growth (YoY)
-97.2%
Valuation Premium vs History
+4.9% premium
PE vs Historical
1.9 vs 1.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.9%
(market-implied from PE analysis)
1-Year Target
$2.18
(+5%)
2-Year Target
$2.29
(+10%)
3-Year Target
$2.40
(+15%)
3-Yr Target (if PE normalizes)
(PE: 2→2)
PE COMPRESSION
$2.03
(-2%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: June 23, 2026 7:03 PM ET
Data refreshes hourly during market hours. Next update: 8:03 PM
Data refreshes hourly during market hours. Next update: 8:03 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XRTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 67 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
